Clinical AI, drug discovery, devices, and regulatory approvals.
An exploratory analysis of the phase III NIMBLE trial showed that the investigational siRNA therapy cemdisiran reduced hospitalizations and myasthenic crises in generalized myasthenia gravis.
A MedPage Today roundup shows physicians using social media to discuss sexual assault prevention, forensic exam billing, and the language of disease origin.
The revised pilot shifts 21 drugs from upfront discounts to post-claim rebates, expanding a controversial program despite hospital opposition.
A weekly MedPage Today roundup highlights recent court cases involving violence against nurses, medical malpractice awards, and healthcare fraud.
The latest Readout LOUD episode tackles science mistrust, a UniQure gene therapy update, Beam's lawsuit against a Chinese rival, and shifting GLP-1 marketing.
Open-label data from the ADAPT SERON trial show sustained symptom improvement over 52 weeks in generalized myasthenia gravis patients lacking anti-AChR antibodies.
A new Science special issue highlights how sex-dependent differences in pain, aging, and menopause remain understudied and underfunded.
The partners will split profits evenly on a new series of experimental immunology antibodies, with Regeneron leading R&D and Sanofi handling commercialization.
Two EASD trials show investigational diabetes drugs achieve meaningful weight loss, but adverse events led many participants to stop treatment.
Chinese biotech leaders used Jefferies' inaugural Shanghai event to argue that their drug-development speed gives them an edge over the US and Europe.
A large MRI study identifies distinct patterns of accelerated brain aging tied to Alzheimer's, mild cognitive impairment, psychiatric disorders, and addiction.
A large study finds higher rates of nail separation and discoloration among GLP-1 users, but the association weakens in stricter analyses.
A global analysis finds that preventable infections still drive 12% of cancer diagnoses, with regional gaps in prevention and treatment.
A proposed overhaul of the National Health Interview Survey would remove disability-related questions, threatening data on a group with high chronic-disease burden.
HHS Secretary Robert F. Kennedy Jr. said artificial intelligence is 'much better informed than any doctor in the country,' according to the New York Times.
A mid-stage trial found Eli Lilly's experimental combination of Zepbound and the amylin drug eloralintide produced greater weight loss than either alone, though tolerability issues led many participants to stop treatment.
The proposed merger is the third major hospital combination announced in Minnesota in six months, drawing regulatory scrutiny and union concerns.
With standard chemoimmunotherapy yielding only 9-12 months of survival, Richter's transformation to DLBCL is driving a wave of novel combination trials.